RT Journal Article
SR Electronic
T1 Probing Autism and ADHD subtypes using cortical signatures of the T1w/T2w-ratio and morphometry
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24311239
DO 10.1101/2024.08.08.24311239
A1 Norbom, Linn B.
A1 Syed, Bilal
A1 Kjelkenes, Rikka
A1 Rokicki, Jaroslav
A1 Beauchamp, Antoine
A1 Nerland, Stener
A1 Kushki, Azadeh
A1 Anagnostou, Evdokia
A1 Arnold, Paul
A1 Crosbie, Jennifer
A1 Kelley, Elizabeth
A1 Nicolson, Robert
A1 Schachar, Russell
A1 Taylor, Margot J.
A1 Westlye, Lars T.
A1 Tamnes, Christian K.
A1 Lerch, Jason P.
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311239.abstract
AB Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are neurodevelopmental conditions that share genetic etiology and frequently co-occur. Given this comorbidity and the well-established clinical heterogeneity within both conditions, identifying individuals with similar brain signatures may be valuable for predicting clinical outcomes and tailoring treatment strategies. Cortical myelination is a prominent developmental process, and its disruption is one of the candidate mechanisms for both disorders. Yet, no studies have attempted to identify subtypes based on T1w/T2w-ratio, a magnetic resonance imaging (MRI) based proxy for intracortical myelin. Moreover, cortical variability likely arises from numerous biological pathways, and multimodal approaches can effectively integrate several cortical metrics by fusing them into a single network. We analyzed data from 310 youths aged 2.6-23.6 years, obtained from the Province of Ontario Neurodevelopmental (POND) Network consisting of individuals diagnosed with ASD (n=136), ADHD (n=100), and typically developing (TD) individuals (n=74). We first tested for differences in cortical microstructure between diagnostic categories and controls, as assessed by the T1w/T2w-ratio. We then performed unimodal (T1w/T2w-ratio) and multimodal (T1w/T2w-ratio, cortical thickness, and surface area) spectral clustering to identify diagnostic-blind subgroups. As hypothesized, we did not find statistically significant case-control differences in T1w/T2w-ratio. Unimodal clustering mostly isolated single individual- or minority clusters, driven by image quality and intensity outliers. Multimodal clustering suggested three distinct subgroups, which transcended diagnostic boundaries, showing distinct cortical patterns but similar clinical and cognitive profiles. T1w/T2w-ratio features were the most relevant for demarcation, followed by surface area. While there do not appear to be considerable differences at the diagnostic group level, multimodal clustering using the T1w/T2w-ratio holds promise for identifying biologically similar subsets among individuals with neurodevelopmental conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Research Council of Norway The South-Eastern Norway Regional Health Authority The ERA-Net Cofund through the ERA PerMed project IMPLEMENT, and the European Research Council under the European Unions Horizon 2020 research and Innovation program (ERC StG Grant #802998).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Hospital for Sick Children, Toronto, Canada gave ethical approval for this work (1000012230).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. The statistical code used in the present paper is available online (https://osf.io/dfvk9/).